• Montagu Acquires Tyber Medical 

    by | Jan 15, 2025 3:53 pm | Medical Devices

    Montagu Private Equity announced on January 14 the acquisition of Tyber Medical for an undisclosed price. With this transaction, Montagu will merge Tyber Medical with its portfolio companies Intech and Resolve Surgical Technologies to create a new platform.   Tyber Medical is an orthopedic medical device manufacturer providing rapid... Read More »

  • Takara Bio USA Holdings Acquires Curio Bioscience 

    by | Jan 15, 2025 3:52 pm | Biotechnology

    On January 15, Takara Bio USA Holdings Inc., a wholly owned subsidiary of Takara Bio Inc., announced that it acquired Curio Bioscience.   Curio Bioscience is a biotechnology company that is advancing a new generation of high-precision tools for the life sciences industry. The company has developed spatial biology capabilities to map the... Read More »

  • 2025 Kicks off With Several Big Biopharma Deals

    by | Jan 15, 2025 10:25 am | Biotechnology, Pharmaceuticals

    With the JP Morgan 43rd Annual Healthcare Conference underway in San Francisco this week, the Biotechnology and Pharmaceutical (Biopharma) sectors are seeing a flurry of activity. Many large-scale acquisitions and licensing agreements are being announced, setting the tone for an eventful year ahead in the industry. So far this year, 14 Biopharma... Read More »

  • In Motion Physical Therapy Joins PE-Backed Ivy Rehab

    by | Jan 14, 2025 12:27 pm | Private Equity, Rehabilitation

    Private equity-backed Ivy Rehab announced in January 2025 that it has partnered with In Motion Physical Therapy in Downingtown, Pennsylvania. Financial terms of the deal were not disclosed.  In Motion Physical Therapy is a provider of outpatient physical therapy in Pennsylvania. The company is led by a team of therapists specializing in... Read More »

  • West Physics Consulting Acquires Mid-South Medical Physics in Arkansas

    by | Jan 14, 2025 12:25 pm | Other Services

    West Physics Consulting announced on January 13 that it has entered into a strategic partnership agreement with Mid-South Medical Physics. The partnership with Mid-South includes a multi-phase acquisition of Mid-South by West Physics, allowing Mid-South’s owner and President, Mr. Paul Beck, to gradually retire as West Physics supports him... Read More »
​​Talaris Therapeutics Merges with Tourmaline Bio

​​Talaris Therapeutics Merges with Tourmaline Bio

by | Jun 23, 2023 3:14 pm | Biotechnology

Talaris Therapeutics, Inc. announced on June 22 that it entered an agreement to merge with Tourmaline Bio, Inc. According to data captured in the LevinPro HC database, this transaction represents the 76th Biotechnology transaction of 2023.  Talaris stockholders are expected to receive $3.43 per Talaris share for a total price of more than $144.62 million. Tourmaline stockholders are expected to own 78.7% of the combined company and Talaris stockholders are expected to own 21.3% of the combined company, each on a fully diluted basis. Talaris anticipates making a cash dividend of up to approximately $64.8 million to its stockholders prior to the closing of the Merger. Talaris Therapeutics is... Read More »
Pyxis Oncology Acquires Apexigen

Pyxis Oncology Acquires Apexigen

by | May 25, 2023 1:56 pm | Biotechnology

Pyxis Oncology announced on May 24 that it acquired Apexigen, Inc. for $16 million.  Founded in 2010, Apexigen, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology. Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates and immunotherapies. It is funded by the Longwood Fund, a Boston-based venture capital firm.  This acquisition was announced nearly a year after Apexigen went public by a merger with Brookline Capital Acquisition Corp.  According to data captured in the LevinPro HC database, this acquisition represents the 61st... Read More »
​​Talaris Therapeutics Merges with Tourmaline Bio

Bavarian Nordic Closes Acquisition of Emergent BioSolutions’ Travel Health Business

by | May 22, 2023 3:16 pm | Biotechnology

Gaithersburg, Maryland-based Emergent BioSolutions Inc., a specialty biopharmaceutical company, announced that it closed on the sale of its portfolio of travel vaccines to Bavarian Nordic. The transaction was initially announced on February 15, 2023.  The portfolio includes Vivotif and Vaxchora, which prevent typhoid fever and cholera, respectively. Emergent BioSolutions is also selling a Phase III vaccine candidate for the prevention of Chikungunya virus. Emergent received $270 million and may receive up to an additional $110 million in potential future milestone payments. Wells Fargo Securities, LLC served as financial advisor, and Barnes & Thornburg LLP served as legal counsel... Read More »
Pyxis Oncology Acquires Apexigen

Astellas Pharma to Acquire Iveric Bio for $5.9 Billion

by | May 2, 2023 9:58 am | Biotechnology

Astellas Pharma announced that it has entered into a definitive agreement to acquire Iveric Bio for $40 per share in cash, for a total equity value of approximately $5.9 billion. The acquisition is expected to be completed in the third quarter of 2023. Under the terms of the agreement, Iveric Bio will become an indirectly wholly owned subsidiary of Astellas Pharma. The acquisition includes avacincaptad pegol, which is under evaluation for the treatment of geographic atrophy. Iveric Bio is a biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The company delivers treatments designed to address... Read More »
Pyxis Oncology Acquires Apexigen

Merck Acquires Prometheus Biosciences for $10.8 Billion

by | Apr 17, 2023 9:57 am | Biotechnology

Merck & Co., Inc. announced on April 17 that it will acquire, through a subsidiary, Prometheus Biosciences for $200.00 per share for a total equity value of approximately $10.8 billion. The transaction is expected to close in the third quarter of 2023. Morgan Stanley & Co. LLC acted as financial advisor to Merck and Paul, Weiss, Rifkind, Wharton & Garrison LLP as its legal advisors. Centerview Partners LLC and Goldman Sachs acted as financial advisors to Prometheus and Latham & Watkins LLP as the company’s legal advisor. Prometheus Biosciences is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and... Read More »
​​Talaris Therapeutics Merges with Tourmaline Bio

Miltenyi Biotec Acquires lino Biotech

by | Mar 23, 2023 11:36 am | Biotechnology

Miltenyi Biotec, a Bergisch Gladbach, Germany-based company, announced on March 22 that it acquired lino Biotech. Miltenyi Biotec purchased 100% of the shares from investors such as Switzerland-based Roche Venture Fund and Germany-based Hightech-Grunderfonds. Brown Gibbons Lang & Company initiated the transaction and acted as the exclusive financial advisor to lino Biotech.  lino Biotech is the world’s only company specialized in focal molography – a new method for measuring molecular interactions in living cells or crude biological samples. It is based in Zurich and was founded in 2020. Miltenyi Biotec has been a global provider of products and services for biomedical research... Read More »